MBRX
Moleculin Biotech, Inc.
stockNASDAQ
moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. the other portfolio targets the metabolism of tumors.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 6.19 | 2026-10-20 | +49.27% | 4.836 |
| 1M | 0.57 | 2026-09-28 | +1523.90% | 111.040 |
| 3M | 2.19 | 2026-07-27 | +321.92% | 20.939 |
| 6M | 2.54 | 2026-04-27 | +263.78% | 9.399 |
| 1Y | 12.40 | 2025-10-27 | -25.47% | 4.974 |
| 2Y | 65.50 | 2024-10-28 | -85.89% | — |
| 5Y | 997.50 | 2021-10-27 | -99.07% | 1.316 |
Moleculin Biotech, Inc. (NASDAQ:MBRX) stock price today is $9.24, and today's volume is 176,011. MBRX is up 30.416% today. The 30 day average volume is 833,127. MBRX market cap is $9.42M with 1.02M shares outstanding.